b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29775310</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>05</Month>\n            <Day>20</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>05</Month>\n            <Day>20</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1520-4804</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>61</Volume>\n                    <Issue>11</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>06</Month>\n                        <Day>14</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of medicinal chemistry</Title>\n                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>4978-4992</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.8b00421</ELocationID>\n            <Abstract>\n                <AbstractText>Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers. Inhibitors of BRAF and MEK kinases are approved for the treatment of BRAF mutant melanoma, but resistance frequently emerges, often mediated by increased signaling through ERK1/2. Here, we describe the fragment-based generation of ERK1/2 inhibitors that block catalytic phosphorylation of downstream substrates such as RSK but also modulate phosphorylation of ERK1/2 by MEK without directly inhibiting MEK. X-ray crystallographic and biophysical fragment screening followed by structure-guided optimization and growth from the hinge into a pocket proximal to the C-\xce\xb1 helix afforded highly potent ERK1/2 inhibitors with excellent kinome selectivity. In BRAF mutant cells, the lead compound suppresses pRSK and pERK levels and inhibits proliferation at low nanomolar concentrations. The lead exhibits tumor regression upon oral dosing in BRAF mutant xenograft models, providing a promising basis for further optimization toward clinical pERK1/2 modulating ERK1/2 inhibitors.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Heightman</LastName>\n                    <ForeName>Tom D</ForeName>\n                    <Initials>TD</Initials>\n                    <Identifier Source="ORCID">0000-0002-9109-4748</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Berdini</LastName>\n                    <ForeName>Valerio</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Braithwaite</LastName>\n                    <ForeName>Hannah</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Buck</LastName>\n                    <ForeName>Ildiko M</ForeName>\n                    <Initials>IM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cassidy</LastName>\n                    <ForeName>Megan</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Castro</LastName>\n                    <ForeName>Juan</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Courtin</LastName>\n                    <ForeName>Aur\xc3\xa9lie</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Day</LastName>\n                    <ForeName>James E H</ForeName>\n                    <Initials>JEH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>East</LastName>\n                    <ForeName>Charlotte</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fazal</LastName>\n                    <ForeName>Lynsey</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Graham</LastName>\n                    <ForeName>Brent</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Griffiths-Jones</LastName>\n                    <ForeName>Charlotte M</ForeName>\n                    <Initials>CM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lyons</LastName>\n                    <ForeName>John F</ForeName>\n                    <Initials>JF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Martins</LastName>\n                    <ForeName>Vanessa</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Muench</LastName>\n                    <ForeName>Sandra</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Munck</LastName>\n                    <ForeName>Joanne M</ForeName>\n                    <Initials>JM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Norton</LastName>\n                    <ForeName>David</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>O\'Reilly</LastName>\n                    <ForeName>Marc</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Palmer</LastName>\n                    <ForeName>Nick</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pathuri</LastName>\n                    <ForeName>Puja</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Reader</LastName>\n                    <ForeName>Michael</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rees</LastName>\n                    <ForeName>David C</ForeName>\n                    <Initials>DC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rich</LastName>\n                    <ForeName>Sharna J</ForeName>\n                    <Initials>SJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Richardson</LastName>\n                    <ForeName>Caroline</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Saini</LastName>\n                    <ForeName>Harpreet</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Thompson</LastName>\n                    <ForeName>Neil T</ForeName>\n                    <Initials>NT</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wallis</LastName>\n                    <ForeName>Nicola G</ForeName>\n                    <Initials>NG</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Walton</LastName>\n                    <ForeName>Hugh</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wilsher</LastName>\n                    <ForeName>Nicola E</ForeName>\n                    <Initials>NE</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Woolford</LastName>\n                    <ForeName>Alison J-A</ForeName>\n                    <Initials>AJ</Initials>\n                    <Identifier Source="ORCID">0000-0002-6453-5819</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cooke</LastName>\n                    <ForeName>Michael</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sygnature Discovery Ltd., BioCity , Pennyfoot Street , Nottingham , NG1 1GF , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cousin</LastName>\n                    <ForeName>David</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sygnature Discovery Ltd., BioCity , Pennyfoot Street , Nottingham , NG1 1GF , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Onions</LastName>\n                    <ForeName>Stuart</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sygnature Discovery Ltd., BioCity , Pennyfoot Street , Nottingham , NG1 1GF , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shannon</LastName>\n                    <ForeName>Jonathan</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sygnature Discovery Ltd., BioCity , Pennyfoot Street , Nottingham , NG1 1GF , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Watts</LastName>\n                    <ForeName>John</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sygnature Discovery Ltd., BioCity , Pennyfoot Street , Nottingham , NG1 1GF , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Murray</LastName>\n                    <ForeName>Christopher W</ForeName>\n                    <Initials>CW</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge , CB4 0QA , U.K.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>31</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Med Chem</MedlineTA>\n            <NlmUniqueID>9716531</NlmUniqueID>\n            <ISSNLinking>0022-2623</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.24</RegistryNumber>\n                <NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.24</RegistryNumber>\n                <NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055162" MajorTopicYN="N">Biocatalysis</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>5</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29775310</ArticleId>\n            <ArticleId IdType="doi">10.1021/acs.jmedchem.8b00421</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'